GLP1R and peripheral arterial disease: Among pharmacologic options, SGLT2is and GLP-1 RAs are recommended as part of the therapeutic strategy in individuals with T2DM and PAD, especially those with an estimated glomerular filtration rate (eGFR) above 30 mL/min/1.73 m2 [11].